Trofile HIV co-receptor usage assay

Expert Opinion on Medical Diagnostics

Volumn 3, Issue 2, 2009, Pages 181-191

  Low, Andrew J ^a,b   McGovern, Rachel A ^b   Harrigan, P Richard ^b,c  

^a BRITISH COLUMBIA CENTRE FOR EXCELLENCE IN HIV AIDS   (Canada)

^b University of British Columbia ^*  (Australia)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

CCR5 antagonist; Co receptor; HIV; Maraviroc; Phenotype; Trofile

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; CHEMOKINE RECEPTOR CXCR4; CHEMOKINE RECEPTOR CXCR4 ANTAGONIST; MARAVIROC; PLACEBO; UNCLASSIFIED DRUG; VIRCRIVIROC; VIRUS RNA;

BIOASSAY; CLINICAL TRIAL; DIAGNOSTIC TEST; EMBRYO; GENOTYPE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MEDICAL LITERATURE; PHENOTYPE; REVIEW; TREATMENT OUTCOME; TREATMENT RESPONSE; VIRUS CULTURE; VIRUS ENTRY; VIRUS INHIBITION; VIRUS LOAD; VIRUS REPLICATION; VIRUS RESISTANCE; VIRUS TROPISM; VIRUS VIRULENCE;

EID: 77953391670     PISSN: 17530059     EISSN: 17530067     Source Type: Journal    
DOI: 10.1517/17530050802708981     Document Type: Review

References (57)

1. Deng H, Liu R, Ellmeier W, et al. Identification of a major co-receptor for primary isolates of HIV-1. Nature 1996;381:661-666
2. Dragic T, Litwin V, Allaway GP, et al. HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5. Nature 1996;381:667-673
3. Berger EA, Murphy PM, Farber JM. Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease [Review]. Annu Rev Immunol 1999;17:657-700
4. Wilkin TJ, Su Z, Kuritzkes DR, et al. HIV type 1 chemokine coreceptor use among antiretroviral-experienced patients screened for a clinical trial of a CCR5 inhibitor: AIDS Clinical Trial Group A5211. Clin Infect Dis 2007;44(4):591-595
5. Van't Wout A, Coakley E, Reeves J, et al. Dynamics of emergence of CXCR4-using HIV in clinical samples as detected by Trofile and MT-2 assays. [abstract]. Antivir Ther 2008;13(Suppl 3): A93
6. Saag MS, Ive P, Heera J, et al. A multicenter, randomized, double-blind, comparative trial of a novel CCR5 antagonist, maraviroc versus efavirenz, both in combination with Combivir (zidovudine [ZDV]/lamivudine [3TC]), for the treatment of antiretroviral naive subjects infected with R5 HIV-1: week 48 results of the MERIT study [abstract WESS104]. 4th IAS Conference on HIV Pathogenesis, Treatment, and Prevention. Sydney, Australia July 22-25, 2007
7. Strizki JM, Tremblay C, Xu S, et al. Discovery and characterization of vicriviroc (SCH 417690), a CCR5 antagonist with potent activity against human immunodeficiency virus type 1. Antimicrob Agents Chemother 2005;49(12):4911-4919
8. Maeda K, Nakata H, Ogata H, et al. The current status of, and challenges in, the development of CCR5 inhibitors as therapeutics for HIV-1 infection. Curr Opin Pharmacol 2004;4(5):447-452
9. Seibert C, Sakmar TP. Small-molecule antagonists of CCR5 and CXCR4: A promising new class of anti-HIV-1 drugs. Curr Pharm Des 2004;10(17):2041-2062
10. Westby M, Van der Ryst E. CCR5 antagonists: Host-targeted antivirals for the treatment of HIV infection. Antivir Chem Chemother 2005;16(6):339-354
11. Mayer H, Van der Ryst E, Saag M, et al. Safety and efficacy of maraviroc, a novel CCR5 antagonist, when used in combination with optimized background therapy for the treatment of antiretroviral-experiences subjects infected with dual/mixed-tropic HIV-1:24-week results of a phase 2b exploratory trial [abstract THLB0215]. XVI International AIDS Conference, Toronto, Ontario, Canada August 13-18, 2006
12. Whitcomb JM, Huang W, Fransen S, et al. Development and characterization of a novel single-cycle recombinant-virus assay to determine human immunodeficiency virus type 1 coreceptor tropism. Antimicrob Agents Chemother 2007;51(2):566-575
13. Huang W, Wrin M, Yap J, et al. A rapid multi-functional HIV-1 entry assay for measuring drug susceptibility, co-receptor tropism, and antibody neutralization. Program and Abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapeutics. 16-19 December 2001; Chicago. Washington, DC: American Society for Microbiology; 2001. p. I-1968
14. Lewis M, Simpson P, Fransen S. et al. CXCR4-using virus detected in patients receiving maraviroc in the Phase III studies MOTIVATE 1 and 2 originates from a pre-existing minority of CXCR4-using virus [abstract 56]. 16th International HIV Drug Resistance Workshop, Barbados, West Indies, June 12-16, 2007
15. Lalezari J, Goodrich J, Dejesus E, et al. Efficacy and Safety of Maraviroc plus Optimized Background Therapy in Viremic ART-experienced Patients Infected with CCR5-tropic HIV-1: 24-Week Results of a Phase 2b/3 Study in the US and Canada [abstract 104bLB]. 14th Conference on Retroviruses and Opportunistic Infections, Los Angeles, California, USA, February 25-28, 2007
16. Nelson M, Fätkenheuer G, Konourina I, et al. Efficacy and Safety of Maraviroc plus Optimized Background Therapy in Viremic, ART-experienced Patients Infected with CCR5-tropic HIV-1 in Europe, Australia, and North America: 24-Week Results [abstract 104aLB]. 14th Conference on Retroviruses and Opportunistic Infections, Los Angeles, California, USA, February 25-28, 2007
17. Reeves J, Han D, Hunt P, et al. Enhancements to the Trofile HIV Co-receptor Tropism Assay Enable Improved Detection of CXCR4-using Subpopulations and Earlier Detection of CXCR4-using Viruses in Sequential Patient Samples. Targeting HIV Entry: 3rd International Workshop Washington, DC, December 7-9, 2007
18. Reeves J, Han D, Liu Y, et al. Enhancements to the Trofile HIV Coreceptor Tropism Assay enable reliable detection of CXCR4-using subpopulations at less than 1%. 47th ICAAC, Chicago, USA, September 2007;H-1026
19. Trinh L, Han D, Huang W, et al. Technical validation of an enhanced sensitivity Trofile HIV coreceptor tropism assay for selecting patients for therapy with entry inhibitors targeting CCR5. Antivir Ther 2008;13(Suppl 3): A128
20. Su Z, Reeves J, Krambrink A, et al. Response to vicriviroc in HIV-infected, treatment experienced individuals using an enhanced version of the Trofile HIV coreceptor tropism assay [Trofile (ES)]: reanalysis of ACTG 5211 results. Antivir Ther 2008;13(Suppl 3): A98
21. Fransen S, Bridger G, Whitcomb JM, et al. Suppression of Dualtropic Human Immunodeficiency Virus Type 1 by the CXCR4 Antagonist AMD3100 Is Associated with Efficiency of CXCR4 Use and Baseline Virus Composition. Am Soc Microbiol 2008;52(7):2608-2615
22. Westby M, Lewis M, Whitcomb J, et al. Emergence of CXCR4-using human immunodeficiency virus type 1(HIV-1) variants in a minority of HIV-1-infected patients following treatment with the CCR5 antagonist maraviroc is from a pretreatment CXCR4-using virus reservoir. J Virol 2006;80(10):4909-4920
23. Low AJ, Dong W, Chan D, et al. Current V3 genotyping algorithms are inadequate for predicting X4 co-receptor usage in clinical isolates. AIDS 2007;21:F17-24
24. Raymond S, Delobel P, Mavignier M, et al. Direct sequencing of V3 could be a valuable alternative to phenotypic assays for the routine assessment of HIV-1 tropism. Antivir Ther 2008;13(Suppl 3): A114
25. Moores A, Thielen A, Dong W, et al. Improved detection of X4 virus by V3 genotyping: application to plasma RNA and proviral DNA. Antivir Ther 2008;13(Suppl 3): A99
26. Daumer M, Kaiser R, Klein R, et al. Inferring viral tropism from genotype with massively parallel sequencing: qualitative and quantitative analysis. Antivir Ther 2008;13(Suppl 3): A101
27. Tsibris A, Arnaout R, Korber B, et al. Dynamic HIV-1 escape from vicriviroc therapy in vivo. Antivir Ther 2008;13(Suppl 3): A97
28. Delobel P, Sandres-sauné K, Cazabat M, et al. R5 to X4 switch of the predominant HIV-1 population in cellular reservoirs during effective HAART. J Acquir Immune Defic Syndr 2005;38:382-392
29. th European HIV Drug Resistance Workshop, Budapest Hungary, March 2008
30. Larder BA, Kohli A, Kellam P, et al. Quantitative detection of HIV-1 drug resistance mutations by automated DNA sequencing. Nature 1993;365(6447):671-673
31. Leitner T, Halapi E, Scarlatti G, et al. Analysis of heterogeneous viral populations by direct DNA sequencing. BioTechniques 1993;15(1):120-127
32. Schuurman R, Demeter L, Reichelderfer P, et al. Worldwide evaluation of DNA sequencing approaches for identification of drug resistance mutations in the human immunodeficiency virus type 1 reverse transcriptase. J Clin Microbiol 1999;37(7):2291-2296
33. Van Laethem K, Van Vaerenbergh K, Schmit JC, et al. Phenotypic assays and sequencing are less sensitive than point mutation assays for detection of resistance in mixed HIV-1 genotypic populations. J Acquir Immune Defic Syndr 1999;22(2):107-118
34. Labernardiere JLS, Lebel-Binay JL, Faudo A, et. al. Tropism determination and performance of Phenoscript™ HIV-1 entry inhibitor assay. Antivir Ther 2005;9:S141
35. Skrabal K, Low AJ, Dong W, et al. Determining human immunodeficiency virus coreceptor use in a clinical setting: Degree of correlation between two phenotypic assays and a bioinformatic model. J Clin Microbiol 2007;45(2):279-284
36. Poveda E, Seclen E, Gonzalez MM, et al. Improvement of genotypic algorithms to predict HIV-1 tropism in treatment-experienced patients: correlation with Trofile results. Antivir Ther 2008;13(Suppl 3):A109
37. Pathway Diagnostics. Pathway Diagnostics Announces Commercial Availability of SensiTrop™ HIV Co-receptor Tropism Assay. Malibu, California: Pathway Diagnostics, 2007
38. Delwart EL, Gordon CJ. Tracking changes in HIV-1 envelope quasispecies using DNA heteroduplex analysis. Methods 1997;12(4):348-354
39. Nelson JA, Fiscus SA, Swanstrom R. Evolutionary variants of the human immunodeficiency virus type 1 V3 region characterized by using a heteroduplex tracking assay. J Virol 1997;71(11):8750-8758
40. Nelson JA, Baribaud F, Edwards T, Swanstrom R. Patterns of changes in human immunodeficiency virus type 1 V3 sequence populations late in infection. J Virol 2000;74(18):8494-8501
41. Coetzer M, Cilliers T, Ping LH. al. Genetic characteristics of the V3 region associated with CXCR4 usage in HIV-1 subtype C isolates. Virology 2006;356(1-2):95-105
42. Li W, Webb E, Nary L, Robbins T. SensiTrop QT: A novel molecular diagnostic assay for the detection and quantification of HIV co-receptor tropism [abstract 919]. 15th Conference on Retroviruses and Opportunistic Infections, Boston MA, February 3-6, 2008
43. Tressler R, Valdex H, van der Ryst E, et al. Comparison of results from the SensiTrop vs Trofile assays on 100 samples from the maraviroc expanded access program [abstract 920]. 15th Conference on Retroviruses and Opportunistic Infections, Boston MA, February 3-6, 2008
44. Weiser B, Philpott S, Klimkait T. al. Swiss HIV Cohort Study. HIV-1 coreceptor usage and CXCR4-specific viral load predict clinical disease progression during combination antiretroviral therapy. AIDS 2008;22(4):469-479
45. Hamy F, Garcia O, Klimkait T. Coreceptor tropism of HIV in clinical sample dissected by Phenotyping [abstract 009]. 4th IAS Conference on HIV Pathogenesis, Treatment and Prevention, Sydney, Australia, July 2007
46. Merriweather AG. Study Reaffirms Superiority of Trofile (TM) Assay. Reuters, UK 2008. Available from: http://uk.reuters.com/article/pressRelease/ idUS221873+19-Dec-2007+PRN20071219?symbol=PFE.N. [Last Accessed 13 January 2008 ]
47. Invirion Diagnostics. Virotect Tropism Assay for HIV-1. Invirion Diagnostics, LLC, 1900;Spring Road, Suite 200 Oak Brook, IL. 2007. Available from: http://www.invirion.com/downloads/virotect/ Virotect- Tropism-Info.pdf. [Last Accessed 7 January 2007 ]
48. Mallal S, Nolan D, Witt C, et al. Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet 2002;359(9308):727-732
49. Mallal S, Phillips E, Carosi G, et al. HLA-B*5701 screening for hypersensitivity to abacavir. N Engl J Med 2008;358(6):568-579
50. Gulick RM, Lalezari J, Goodrick J, et al. Maraviroc for previously treated patients with R5 HIV-1 infection. N Engl J Med 2008;359(14):1429-1441
51. th Conference on Retroviruses and Opportunistic Infections, Los Angeles, CA, February. 2007
52. th Conference on Retroviruses and Opportunistic Infections, Los Angeles, CA, February; 2007
53. th annual meeting, Washington DC, October 25-28, 2008
54. th annual meeting, Washington DC, October 25-28, 2008
55. Su Z, Reeves JD, Krambrink A, et al. Response to vicriviroc in HIV-infected, treatment-experienced individuals using an enhanced version of the Trofile HIV co-receptor tropism assay [Trofile (ES)]: reanalysis of ACTG 5211 results [abstract 88]. XVII International HIV Drug Resistance Workshop, Sitges, Spain, June 10-14, 2008
56. Chi KR. The year of sequencing. Nat Methods 2008;5:11-14
57. th Conference on Retroviruses and Opportunistic Infections, Los Angeles, CA, February; 2007